Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Phase 2 Completed 40 enrolled University of Pittsburgh Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced NSCLC.

Timeline

Start: 2006-06
Primary completion: 2012-02
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Summary

Timeline

Drugs

Indications